The impact of Statins on biological characteristics of stem cells provides a novel explanation for their pleiotropic beneficial and adverse clinical effects

American Journal of Physiology - Cell Physiology

Volumn 309, Issue 8, 2015, Pages C522-C531

  Izadpanah, Reza ^a   Schächtele, Deborah J ^a   Pfnür, Andreas B ^a   Lin, Dong ^a   Slakey, Douglas P ^a   Kadowitz, Philip J ^a   Alt, Eckhard U ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Atherosclerotic plaque; Cardiovascular events; Macrophages; Statin drugs; Stem cells

Indexed keywords

APEX1 PROTEIN; ATM PROTEIN; ATORVASTATIN; BONE MORPHOGENETIC PROTEIN 6; CASPASE 3; CASPASE 8; CASPASE 9; CD14 ANTIGEN; CD4 ANTIGEN; CHECKPOINT KINASE 1; CHOLESTEROL; COLLAGEN TYPE 2; HIGH MOBILITY GROUP A2 PROTEIN; PRAVASTATIN; PROTEIN P16; PROTEIN P53; TRANSCRIPTION FACTOR E2F4; UNCLASSIFIED DRUG; XRCC4 PROTEIN; XRCC6 PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; APOPTOSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CELL AGING; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL DENSITY; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; COLONY FORMING UNIT; GENE EXPRESSION; GENE EXPRESSION PROFILING; GROUPS BY AGE; GROWTH RATE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; MACROPHAGE; MACROPHAGE FUNCTION; MESENCHYMAL STEM CELL; PLEIOTROPY; PRIORITY JOURNAL; SENESCENCE; SPINDLE CELL; U937 CELL LINE; UPREGULATION; ADIPOSE TISSUE; AGING; CELL CULTURE; CELL CYCLE; CYTOLOGY; DRUG EFFECTS; MESENCHYMAL STROMA CELL; MIDDLE AGED; PHYSIOLOGY; YOUNG ADULT;

ADIPOSE TISSUE; ADULT; AGED; AGING; CELL CYCLE; CELLS, CULTURED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; YOUNG ADULT;

EID: 84945205241     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00406.2014     Document Type: Article

References (56)

1. Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, Patchett A, Monaghan R, Currie S, Stapley E, Albers-Schonberg G, Hensens O, Hirshfield J, Hoogsteen K, Liesch J, Springer J. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 77: 3957-3961, 1980.
2. Alt E, Pinkernell K, Scharlau M, Coleman M, Fotuhi P, Nabzdyk C, Matthias N, Gehmert S, Song YH. Effect of freshly isolated autologous tissue resident stromal cells on cardiac function and perfusion following acute myocardial infarction. Int J Cardiol 144: 26-35, 2010.
3. Alt EU, Senst C, Murthy SN, Slakey DP, Dupin CL, Chaffin AE, Kadowitz PJ, Izadpanah R. Aging alters tissue resident mesenchymal stem cell properties. Stem Cell Res 8: 215-225, 2012.
4. Anghileri E, Marconi S, Pignatelli A, Cifelli P, Galie M, Sbarbati A, Krampera M, Belluzzi O, Bonetti B. Neuronal differentiation potential of human adipose-derived mesenchymal stem cells. Stem Cells Dev 17: 909-916, 2008.
5. Assmus B, Urbich C, Aicher A, Hofmann WK, Haendeler J, Rossig L, Spyridopoulos I, Zeiher AM, Dimmeler S. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res 92: 1049-1055, 2003.
6. Bai X, Yan Y, Song YH, Seidensticker M, Rabinovich B, Metzele R, Bankson JA, Vykoukal D, Alt E. Both cultured and freshly isolated adipose tissue-derived stem cells enhance cardiac function after acute myocardial infarction. Eur Heart J 31: 489-501, 2010.
7. Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother 10: 2973-2985, 2009.
8. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109: III50-III57, 2004.
9. Bouchard MH, Dragomir A, Blais L, Berard A, Pilon D, Perreault S. Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol 63: 698-708, 2007.
10. Brouilette SW, Moore JS, McMahon AD, Thompson JR, Ford I, Shepherd J, Packard CJ, Samani NJ. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 369: 107-114, 2007.
11. Cousin B, Andre M, Arnaud E, Penicaud L, Casteilla L. Reconstitution of lethally irradiated mice by cells isolated from adipose tissue. Biochem Biophys Res Commun 301: 1016-1022, 2003.
12. Cramer C, Freisinger E, Jones RK, Slakey DP, Dupin CL, Newsome ER, Alt EU, Izadpanah R. Persistent high glucose concentrations alter the regenerative potential of mesenchymal stem cells. Stem Cells Dev 19: 1875-1884, 2010.
13. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, Andriolo G, Sun B, Zheng B, Zhang L, Norotte C, Teng PN, Traas J, Schugar R, Deasy BM, Badylak S, Buhring HJ, Giacobino JP, Lazzari L, Huard J, Peault B. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3: 301-313, 2008.
14. da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 119: 2204-2213, 2006.
15. de Boer OJ, van der Wal AC, Becker AE. Atherosclerosis, inflammation, and infection. J Pathol 190: 237-243, 2000.
16. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, Peacocke M, Campisi J. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92: 9363-9367, 1995.
17. Doran AC, Meller N, McNamara CA. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol 28: 812-819, 2008.
18. Flavahan NA. Atherosclerosis or lipoprotein-induced endothelial dysfunction. Potential mechanisms underlying reduction in EDRF/nitric oxide activity. Circulation 85: 1927-1938, 1992.
19. Foody JM, Shah R, Galusha D, Masoudi FA, Havranek EP, Krumholz HM. Statins and mortality among elderly patients hospitalized with heart failure. Circulation 113: 1086-1092, 2006.
20. Freisinger E, Cramer C, Xia X, Murthy SN, Slakey DP, Chiu E, Newsome ER, Alt EU, Izadpanah R. Characterization of hematopoietic potential of mesenchymal stem cells. J Cell Physiol 225: 888-897, 2010.
21. Gronholdt ML, Nordestgaard BG, Bentzon J, Wiebe BM, Zhou J, Falk E, Sillesen H. Macrophages are associated with lipid-rich carotid artery plaques, echolucency on B-mode imaging, and elevated plasma lipid levels. J Vasc Surg 35: 137-145, 2002.
22. Hamann PD, Cooper RG, McHugh NJ, Chinoy H. Statin-induced necrotizing myositis-a discrete autoimmune entity within the “statininduced myopathy spectrum”. Autoimmun Rev 12: 1177-1181, 2013.
23. Hedman M, Neuvonen PJ, Neuvonen M, Holmberg C, Antikainen M. Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin Pharmacol Ther 75: 101-109, 2004.
24. Hognestad A, Dickstein K, Myhre E, Snapinn S, Kjekshus J. Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure. Am J Cardiol 93: 603-606, 2004.
25. Ilmer M, Vykoukal J, Recio Boiles A, Coleman M, Alt E. Two sides of the same coin: stem cells in cancer and regenerative medicine. FASEB J 28: 2748-2761, 2014.
26. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292: 1160-1164, 2001.
27. Izadpanah R, Trygg C, Patel B, Kriedt C, Dufour J, Gimble JM, Bunnell BA. Biologic properties of mesenchymal stem cells derived from bone marrow and adipose tissue. J Cell Biochem 99: 1285-1297, 2006.
28. Jing Y, Han Z, Liu Y, Sun K, Zhang S, Jiang G, Li R, Gao L, Zhao X, Wu D, Cai X, Wu M, Wei L. Mesenchymal stem cells in inflammation microenvironment accelerates hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition. PLoS One 7: e43272, 2012.
29. Kim YM, Jeon ES, Kim MR, Jho SK, Ryu SW, Kim JH. Angiotensin II-induced differentiation of adipose tissue-derived mesenchymal stem cells to smooth muscle-like cells. Int J Biochem Cell Biol 40: 2482-2491, 2008.
30. Leuschen J, Mortensen EM, Frei CR, Mansi EA, Panday V, Mansi I. Association of statin use with cataracts: a propensity score-matched analysis. JAMA Ophthalmol 131: 1427-1434, 2013.
31. Limana F, Zacheo A, Mocini D, Mangoni A, Borsellino G, Diamantini A, De Mori R, Battistini L, Vigna E, Santini M, Loiaconi V, Pompilio G, Germani A, Capogrossi MC. Identification of myocardial and vascular precursor cells in human and mouse epicardium. Circ Res 101: 1255-1265, 2007.
32. Lu SH, Wei CF, Yang AH, Chancellor MB, Wang LS, Chen KK. Isolation and characterization of human muscle-derived cells. Urology 74: 440-445, 2009.
33. Metzele R, Alt C, Bai X, Yan Y, Zhang Z, Pan Z, Coleman M, Vykoukal J, Song YH, Alt E. Human adipose tissue-derived stem cells exhibit proliferation potential and spontaneous rhythmic contraction after fusion with neonatal rat cardiomyocytes. FASEB J 25: 830-839, 2011.
34. Murinson BB, Haughey NJ, Maragakis NJ. Selected statins produce rapid spinal motor neuron loss in vitro. BMC Musculoskelet Disord 13: 100, 2012.
35. Nombela-Arrieta C, Ritz J, Silberstein LE. The elusive nature and function of mesenchymal stem cells. Nat Rev Mol Cell Biol 12: 126-131, 2011.
36. Olivieri F, Mazzanti I, Abbatecola AM, Recchioni R, Marcheselli F, Procopio AD, Antonicelli R. Telomere/telomerase system: a new target of statins pleiotropic effect? Curr Vasc Pharmacol 10: 216-224, 2012.
37. Perreault S, Blais L, Dragomir A, Bouchard MH, Lalonde L, Laurier C, Collin J. Persistence and determinants of statin therapy among middleaged patients free of cardiovascular disease. Eur J Clin Pharmacol 61: 667-674, 2005.
38. Perreault S, Blais L, Lamarre D, Dragomir A, Berbiche D, Lalonde L, Laurier C, St-Maurice F, Collin J. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol 59: 564-573, 2005.
39. Poluzzi E, Strahinja P, Lanzoni M, Vargiu A, Silvani MC, Motola D, Gaddi A, Vaccheri A, Montanaro N. Adherence to statin therapy and patients’ cardiovascular risk: a pharmacoepidemiological study in Italy. Eur J Clin Pharmacol 64: 425-432, 2008.
40. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276: 71-74, 1997.
41. Ray JG, Gong Y, Sykora K, Tu JV. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med 165: 62-67, 2005.
42. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126, 1999.
43. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol 57: 791-804, 1995.
44. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375: 735-742, 2010.
45. Schober A, Bernhagen J, Thiele M, Zeiffer U, Knarren S, Roller M, Bucala R, Weber C. Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. Circulation 109: 380-385, 2004.
46. Senst C, Nazari-Shafti T, Kruger S, Bentrup KH, Dupin CL, Chaffin AE, Srivastav SK, Worner PM, Abdel-Mageed AB, Alt EU, Izadpanah R. Prospective dual role of mesenchymal stem cells in breast tumor microenvironment. Breast Cancer Res Treat 137: 69-79, 2013.
47. Sharpless NE, DePinho RA. Telomeres, stem cells, senescence, and cancer. J Clin Invest 113: 160-168, 2004.
48. Stolzing A, Coleman N, Scutt A. Glucose-induced replicative senescence in mesenchymal stem cells. Rejuvenation Res 9: 31-35, 2006.
49. Talens-Visconti R, Bonora A, Jover R, Mirabet V, Carbonell F, Castell JV, Gomez-Lechon MJ. Human mesenchymal stem cells from adipose tissue: differentiation into hepatic lineage. Toxicol In Vitro 21: 324-329, 2007.
50. Tierney EF, Thurman DJ, Beckles GL, Cadwell BL. Association of statin use with peripheral neuropathy in the US population 40 years of age or older. J Diabetes 5: 207-215, 2013.
51. Traktuev DO, Merfeld-Clauss S, Li J, Kolonin M, Arap W, Pasqualini R, Johnstone BH, March KL. A population of multipotent CD34-positive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks. Circ Res 102: 77-85, 2008.
52. Trapani L, Pallottini V. Age-related hypercholesterolemia and HMGCoA reductase dysregulation: sex does matter (a gender perspective). Curr Gerontol Geriatr Res: 420139, 2010.
53. Wainstein M, Costa M, Ribeiro J, Zago A, Rogers C. Vulnerable plaque detection by temperature heterogeneity measured with a guidewire system: clinical, intravascular ultrasound and histopathologic correlates. J Invasive Cardiol 19: 49-54, 2007.
54. Wallach Kildemoes H, Vass M, Hendriksen C, Andersen M. Statin utilization according to indication and age: a Danish cohort study on changing prescribing and purchasing behaviour. Health Policy 108: 216-227, 2012.
55. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 15: 551-561, 1995.
56. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 7: 211-228, 2001.